BCRX vs DXCM
BioCryst Pharmaceuticals, Inc. vs Dexcom — AI-powered side-by-side comparison
BCRX
BioCryst Pharmaceuticals, Inc.
59
Buy
VS
| Metric | BCRX | DXCM |
|---|
| AI Score |
59
|
65
|
| Price |
$9.85
|
$89.16
|
| P/E Ratio |
-6.73×
|
35.16×
|
| ROE |
-221.4%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
23.5%
|
62.5%
|
| Debt / Equity |
-0.90×
|
0.53×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
48.8
|
65.4
|
| Beta |
0.554
|
1.41
|
| Expected Upside |
+1.3%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for BCRX versus DXCM.
DXCM leads by 6 points.
DXCM scores 65/100 (Buy) versus BCRX at 59/100 (Buy).
BCRX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 13.9x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical